PE20230486A1 - Polipeptidos y sus usos - Google Patents

Polipeptidos y sus usos

Info

Publication number
PE20230486A1
PE20230486A1 PE2022001740A PE2022001740A PE20230486A1 PE 20230486 A1 PE20230486 A1 PE 20230486A1 PE 2022001740 A PE2022001740 A PE 2022001740A PE 2022001740 A PE2022001740 A PE 2022001740A PE 20230486 A1 PE20230486 A1 PE 20230486A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
polypeptide
present
Prior art date
Application number
PE2022001740A
Other languages
English (en)
Inventor
Neil P King
Carl Walkey
Jing Yang Wang
Brooke Fiala
David Veesler
Alexandra C Walls
Una Nattermann
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of PE20230486A1 publication Critical patent/PE20230486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Abstract

Referido a un polipeptido que comprende o consiste en: (a) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:1 (I3-01 de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8, 9 o las 10 mutaciones siguientes con relacion a la SEQ ID NO:1 estan presentes en el polipeptido: F32Y, H37D/E/K/N/Q/R, F43Q, entre otros; (b) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO: 2 (tetramero O43-38 de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8 o las 9 de las siguientes mutaciones con relacion a la SEQ ID NO:2 estan presentes en el polipeptido: M138D/E/K/N/Q/R/S/T, L139D/N/S, A141S, entre otros; (c) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:3 (trimero O43-38 de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 o las 21 de las siguientes mutaciones con relacion a la SEQ ID NO:3 estan presentes en el polipeptido: R17D/E/K/N/Q/S/T, N19D/E, S20D/E/K/N, entre otros; (d) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:4 (I53_dn5A de tipo silvestre), en donde 1, 2, 3, 4, 5, 6, 7, 8, 9 o las 10 de las siguientes mutaciones con relacion a la SEQ ID NO:4 estan presentes en el polipeptido: R17T, W18D/E/K/N/Q/R/S/T/Y, N19E, E21D, entre otros; o (e) una secuencia de aminoacidos al menos 75 %, 80 %, o hasta 99 % identica a la secuencia de aminoacidos de la SEQ ID NO:5 o 6 (hMPV de tipo silvestre), en donde 1, 2, 3, 4 o las 5 de las siguientes mutaciones con relacion a la SEQ ID NO:5 o 6 estan presentes en el polipeptido: A107D, V112R, T114E, V118R y/o G264D; en donde los residuos entre parentesis son opcionales y pueden estar presentes o pueden estar ausentes en su totalidad o en parte. Tambien se refiere a una proteina de fusion que comprende dicho polipeptido, nanoparticulas y una composicion que comprende dichos polipeptidos, metodos para disenarlos, acido nucleico que codifica dicho polipeptido, vector de expresion, celula hospedera, y metodos para disenar tales polipeptidos.
PE2022001740A 2020-02-14 2021-02-12 Polipeptidos y sus usos PE20230486A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
PCT/US2021/017856 WO2021163481A1 (en) 2020-02-14 2021-02-12 Polypeptides and their use

Publications (1)

Publication Number Publication Date
PE20230486A1 true PE20230486A1 (es) 2023-03-21

Family

ID=77292738

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001740A PE20230486A1 (es) 2020-02-14 2021-02-12 Polipeptidos y sus usos

Country Status (10)

Country Link
US (1) US20230075095A1 (es)
EP (1) EP4103586A4 (es)
JP (1) JP2023513592A (es)
KR (1) KR20220142471A (es)
AU (1) AU2021220958A1 (es)
BR (1) BR112022016197A2 (es)
CL (1) CL2022002215A1 (es)
CO (1) CO2022011395A2 (es)
PE (1) PE20230486A1 (es)
WO (1) WO2021163481A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196871A2 (en) * 2022-04-07 2023-10-12 University Of Washington Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2568788A1 (en) * 2004-06-16 2005-12-29 Dsm Ip Assets B.V. Production of polypeptides by improved secretion
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
CN115947873A (zh) * 2017-04-04 2023-04-11 华盛顿大学 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途

Also Published As

Publication number Publication date
JP2023513592A (ja) 2023-03-31
AU2021220958A1 (en) 2022-09-01
US20230075095A1 (en) 2023-03-09
EP4103586A4 (en) 2024-05-15
CL2022002215A1 (es) 2023-05-05
CO2022011395A2 (es) 2023-01-16
WO2021163481A1 (en) 2021-08-19
KR20220142471A (ko) 2022-10-21
BR112022016197A2 (pt) 2022-10-25
EP4103586A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
Hodel et al. In chromaffin cells, the mammalian Sec1p homologue is a syntaxin 1A-binding protein associated with chromaffin granules.
AR110502A1 (es) Polinucleótidos y polipéptidos de adenovirus
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
DE69434083D1 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
HRP20130194T1 (hr) Imunosupresivni polipeptidi i nukleinske kiseline
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
DE69839553D1 (de) Verfahren zur herstellung von proteinen
AR051837A1 (es) Produccion de proteinas de fusion recombinante dentro de ensamblajes similares a cuerpos proteicos recombinantes (escpr)
AR057884A1 (es) Plantas con caracteristicas de crecimiento mejoradas y un metodo para desarrollarlas
AR065074A1 (es) Peptidos de senalizacion
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
WO2021198706A3 (en) Coronavirus vaccines
AR123158A1 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
PE20230486A1 (es) Polipeptidos y sus usos
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
CO4790156A1 (es) Polipeptidos de membrana de linfocito de mamifero y acidos nucleicos que los codifican
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
CL2023001436A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
PE20220706A1 (es) Muteinas de interleucina-2 para la expansion de celulas t reguladoras
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
EP4302824A3 (en) Compositions and methods for nucleic acid expression and protein secretion in bacteroides